Persistence of Leukemia-Initiating Cells in a Conditional Knockin Model of an Imatinib-Responsive Myeloproliferative Disorder

Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML patients are rarely cured by this therapy perhaps due to imatinib-refractoriness of leukemia-initiating cells (LICs). Evidence for this is limited because of poor engraftment of human CMLLICs in NOD-SCID mice and non-physiol...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Oravecz-Wilson, Katherine I., Philips, Steven T., Yilmaz, Ömer H., Ames, Heather M., Li, Lina, Crawford, Brendan D., Gauvin, Alice M., Lucas, Peter C., Sitwala, Kajal, Downing, James R., Morrison, Sean J., Ross, Theodora S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2763369/
https://ncbi.nlm.nih.gov/pubmed/19647224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2009.06.007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller